TBC1D22A and ovarian carcinoma: Therefore, combined use of TBC1D22A inhibitors may improve the effect of immune checkpoint blockade on ovarian cancer, and TBC1D22A may also act as a molecular marker for screening whether immune checkpoint blockade can be used.